Monogenic causes of elevated HDL cholesterol and implications for development of new therapeutics.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. Unravelling HDL-Looking beyond the Cholesterol Surface to the Quality Within.International journal of molecular sciences · 2018
   Review
2. Multiplexed Targeted Resequencing Identifies Coding and Regulatory Variation Underlying Phenotypic Extremes of High-Density Lipoprotein Cholesterol in Humans.Circulation. Genomic and precision medicine · 2018
   Article
3. HDL Cholesterol Metabolism and the Risk of CHD: New Insights from Human Genetics.Current cardiology reports · 2017
   Review
4. Antilipidemic Drug Therapy Today and in the Future.Handbook of experimental pharmacology · 2016
   Review
5. Novel polymorphisms associated with hyperalphalipoproteinemia and apparent cardioprotection.Journal of clinical lipidology
   Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

3 authors.

Funding

Abstract

Indexed as